Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Leukemia-Lymphoma, Adult T-Cell × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia-Lymphoma, Adult T-Cell 1 Leukemia 1

Interventions

Cyclophosphamide 2 ruxolitinib 1 fludarabine phosphate 1 fludarabine 1 etoposide phosphate 1 brincidofovir 1 Vincristine 1 Raltegravir Potassium 1 Prednisone 1 Etoposide 1 Doxorubicin 1 Bortezomib 1 B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00924170 2023-11-14

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed

18 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡